Enzalutamide response in a panel of prostate cancer cell lines reveals a role for glucocorticoid receptor in enzalutamide resistant disease
Abstract Representative in vitro model systems that accurately model response to therapy and allow the identification of new targets are important for improving our treatment of prostate cancer. Here we describe molecular characterization and drug testing in a panel of 20 prostate cancer cell lines....
Enregistré dans:
Auteurs principaux: | Rebecca Smith, Moqing Liu, Tiera Liby, Nora Bayani, Elmar Bucher, Kami Chiotti, Daniel Derrick, Anne Chauchereau, Laura Heiser, Joshi Alumkal, Heidi Feiler, Peter Carroll, James E. Korkola |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Nature Portfolio
2020
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/708df8dc657045d19f9756d95d497a15 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
A noncanonical AR addiction drives enzalutamide resistance in prostate cancer
par: Yundong He, et autres
Publié: (2021) -
Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses
par: Qiuhui Li, et autres
Publié: (2018) -
The MAO inhibitors phenelzine and clorgyline revert enzalutamide resistance in castration resistant prostate cancer
par: Keliang Wang, et autres
Publié: (2020) -
Comparison of real-life data of abiraterone acetate and enzalutamide in metastatic castration-resistant prostate cancer
par: Ayşe Demirci, et autres
Publié: (2021) -
Stevens-Johnson Syndrome Caused by Enzalutamide: A Case Report and Literature Review
par: Min Deng, et autres
Publié: (2021)